Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
The Effects of Different Modalities of Exercise in Patients With Schizophrenia
Introduction: Numerous studies support the practice of different physical exercise modalities as an effective treatment to address the different problems associated with schizophrenia, reporting that they result in significant…
- Trial name
- NCT04987151
- Testing
- Experimental-Strength training, Experimental-Aerobic training, Experimental-Strength/Aerobic training
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Cardenal Herrera University
Schizophrenia
A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.
- Trial name
- NCT01870999
- Testing
- aripiprazole IM depot, aripiprazole tablets
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Psychotic Disorders
Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention
This is a randomized pilot study of an intervention based on principles of Cognitive Behavioral Therapy (CBT). This intervention is the Health Dialogue Intervention (HDI) and will be compared to a traditional medical model of…
- Trial name
- NCT00980252
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Illinois Chicago
Schizophrenia
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
This clinical study will compare the equivalence of two products containing Paliperidone 100 mg in the form of a prolonged release suspension for injection in patients affected by schizophrenia who are already receiving this…
- Trial name
- NCT03425552
- Testing
- Paliperidone
- Where
- 3 sites in Jordan
- Volunteers
- 70 people
- Sponsor
- Pharmathen S.A.
Schizophrenia, Schizoaffective Disorder
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
Background: In this proposed study, we aim to investigate safety and efficacy of two synthetic retinoids - bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) and…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Cognition
- Trial name
- NCT00534898
- Testing
- Bexarotene, Fenretinide
- Where
- Israel
- Sponsor
- Beersheva Mental Health Center
Schizophrenia, Major Depression
Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection.
- Trial name
- NCT00300404
- Testing
- daraprim, pyrimethamine, folinic acid
- Volunteers
- 40 people
- Sponsor
- Zentrum für Integrative Psychiatrie
Schizophrenia
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
This is a Phase 2, randomized, double-blinded, placebo-controlled, inpatient study to examine the efficacy, safety, and tolerability profile of KarXT in adult subjects diagnosed with DSM-5 schizophrenia who are in an acute…
- Trial name
- EMERGENT-1 (NCT03697252)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 12 sites in United States
- Volunteers
- 182 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
VLT-015 in Patients With Schizophrenia
15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses.
- Trial name
- VLT-015 (NCT05516121)
- Testing
- VLT-015
- Where
- 2 sites in Russia
- Volunteers
- 15 people
- Sponsor
- CF Pharma, LLC
Schizophrenia, Schizoaffective Disorder
Trial of Cognitive Behavioral Therapy for Schizophrenia
The following study addresses the hypothesis that cognitive-behavioral interventions will be effective in reducing positive and negative symptoms of schizophrenia under the conditions of the German health care system.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00300651
- Testing
- Cognitive Behavioral Therapy
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Philipps University Marburg
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00154258
- Testing
- Clozapine
- Volunteers
- 19 people
- Sponsor
- Novartis
Cardiovascular Diseases, Schizophrenia
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
The goal of this clinical trial is to compare the effect of nutritional counseling versus no treatment in patients with schizophenia or bipolar affective disorder.
- Conditions
- Cardiovascular Diseases, Schizophrenia, Psychosis, Bipolar Disorder
- Trial name
- NCT06197048
- Testing
- Nutritional counseling
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Vestre Viken Hospital Trust
Patient Treated With Lithium, With Bipolar or Schizo-affective Disorder, Hospitalized in a Psychiatric Ward
Validation of the French Version of the Lithium Knowledge Test (LKT)
Lithium is a drug used to treat several psychiatric illnesses. This medication requires particular vigilance because it has a narrow therapeutic margin: the dose necessary to obtain an effective treatment is close to the toxic…
- Trial name
- LKT (NCT06033326)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Lille
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- PERFlexS (NCT00460512)
- Testing
- Paliperidone ER
- Where
- 231 sites in Belgium, Bulgaria and 20 more
- Volunteers
- 1,814 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia, Schizoaffective Disorder
Conversion to Antipsychotic Monotherapy
This is a 12-week, with a 32-week follow-up, rater-blind, randomized controlled trial to determine whether patients with chronic schizophrenia or schizoaffective disorder receiving two different antipsychotics simultaneously will…
- Trial name
- MOPE (NCT01368458)
- Testing
- Conversion to Antipsychotic Monotherapy
- Volunteers
- 24 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of…
- Trial name
- NCT01150448
- Testing
- Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B
- Where
- 28 sites in United States, Belgium and 8 more
- Volunteers
- 212 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia Schizoaffective
Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes
Two of the major features of schizophrenia spectrum illness, negative and cognitive symptoms, have been associated with poor functional outcome and burden of illness.
- Trial name
- NCT05414058
- Testing
- Apo-Methylphenidate ER
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia, Schizoaffective Disorder
Improving Antipsychotic Adherence Among Patients With Serious Mental Illness
This is a randomized controlled trial examining the effectiveness of a pharmacy-based intervention designed to improve adherence with antipsychotic medications among patients with serious mental illness.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00057135
- Testing
- Unit of use medication packaging, Mailed reminders to patient when medication refills are due, Note to Mental Health Provider when refill is overdue
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Application of a Mindfulness and Self-Compassion Program in Patients With Schizophrenia. Randomized Controlled Trial.
This is a randomized clinical trial to check whether the quality of life of patients with schizophrenia improves after participation in the mindfulness and self-compassion (MSC) programme.
- Trial name
- ACAMP2020 (NCT04144075)
- Testing
- Mindful Self-Compassion Program, Cognitive Behaviour Therapy Group, Treatment as usual
- Volunteers
- 150 people
- Sponsor
- Gutiérrez-Hernández, ME
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.